More than 110 drugs, capable of penetrating this elusive barrier are currently being evaluated for the treatment of CNS disorders; there are nearly 35 technology platforms for the development of BBB penetrant drugs, claims Roots Analysis
The concept of BBB penetration is anticipated to bring about a paradigm shift in modern healthcare. In fact, experts believe that there is an important relationship between the recent pandemic of Coronavirus disease (COVID-19) and cerebrovascular system, presenting commercial opportunities for players engaged in the development of BBB penetrating drugs.
To order this 400+ page report, which features 145+ figures and 205+ tables, please visit this link
The USD 940 million (by 2030) financial opportunity within the BBB market has been analyzed across the following segments:
- Type of Payment Model Adopted
- Upfront payments
- Milestone payments
- Type of Molecule
- Small Molecules
- Biologics
- Target Disease Indication
- Brain Metastases in Breast Cancer
- Glioblastoma Multiforme
- Hunter Syndrome
- Hurler Syndrome
- Leading Technology Platforms
- G®-Technology
- J-Brain Cargo® Technology
- LRP-1 Technology
- Trojan Horse Technology
- Leading Drug Developers
- 2-BBB
- Angiochem
- ArmaGen
- JCR Pharmaceuticals
- Key Geographical Regions
- North America
- Europe
- Asia-Pacific
The Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics report features the following companies, which we identified to be key players in this domain:
- Angiochem
- ArmaGen
- BioArctic
- Cyclenium Pharma
- Denali Therapeutics
- ICB International
- Iproteos
- JCR Pharmaceuticals
- Lauren Sciences
- Medesis Pharma
- Ossianix
- Vect-Horus
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Market Landscape: Non-Invasive BBB Penetration
5. Market Landscape: BBB Penetrating Drugs
6. Company Profiles
7. Technology Competitiveness Analysis
8. Non-Invasive BBB Penetration Technologies: Popular Approaches
9. Partnerships and Collaborations
10. Analysis of Recent Licensing Agreements
11. Funding and Investment Analysis
12. Patent Analysis
13. Drug Development Strategy Analysis
14. Market Potential of Key Neurological Disorders
15. Likely Partner Analysis
16. Market Forecast
17. Conclusion
18. Executive Insights
19. Appendix 1: Tabulated Data
20. Appendix 2: List of Companies and Organizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/blood-brain-barrier-drug-delivery/310.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415